TDM Not Yet Justified for Non-Anti-TNF IBD Therapies
This narrative review clarifies where exposure-response signals exist for newer biologics and small molecules in inflammatory bowel disease and, critically, why routine therapeutic drug monitoring cannot yet be recommended for any of them.
Could TDM unlock better outcomes for advanced IBD therapies?
Therapeutic drug monitoring (TDM) could enhance the efficacy of non-anti-tumor necrosis factor (TNF) therapies in inflammatory bowel disease (IBD). The review highlights limited but emerging evidence supporting TDM for non-anti-TNF therapies in IBD, potentially guiding dose adjustments. Current findings suggest TDM might improve treatment outcomes for advanced IBD therapies, though research is ongoing and evidence remains limited. TDM may improve non-anti-TNF therapy outcomes in IBD.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.